| Literature DB >> 31673647 |
Desy Cahya Widianingrum1, Cuk Tri Noviandi2, Siti Isrina Oktavia Salasia3.
Abstract
Antibiotics have components to inhibit infections against Staphylococcus aureus, but they depend on judicious use to minimize the incidence of resistance forms. Strategies to improve the current situation include research in finding a new antimicrobial from virgin coconut oil (VCO). The saturated fatty acid, lauric acid (LA) (C12) contain in VCO was reported to have antibacterial activities. This study developed antimicrobial of VCO as an antimicrobial and immunomodulatory agent. Staphylococcus aureus used in this study had been isolated and identified from the mastitis milk crossbreed Etawa goat from Riau, Indonesia. The susceptibility of S. aureus to VCO was tested using the broth dilution method. The inhibition mechanisms of S. aureus had been studied by scanning electron microscopy (SEM) after treatment with VCO, and potential of VCO, which is known in phagocytosis macrophage. In vitro test confirmed the inhibitory effect of VCO on the growth of S. aureus at the concentration of 200 μl (equal to 0.102 % LA). Based on the result of the phagocytosing assay, VCO could increase the ability of the macrophage cells to phagocyte S. aureus significantly at a concentration of 200 μL (equal to 0.102% LA). This study concluded that the VCO could inhibit the growth of S. aureus with destructive mechanisms of bacterial cell walls and increase the ability of the phagocytic immune cells.Entities:
Keywords: Antimicrobial; Immunomodulator; Microbiology; Staphylococcus aureus; Virgin coconut oil
Year: 2019 PMID: 31673647 PMCID: PMC6817632 DOI: 10.1016/j.heliyon.2019.e02612
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Fig. 1Müller Hinton Agar dilution test results of Staphylococcus aureus on the MHA containing VCO with different concentrations. A = MHA without VCO (clear), B = MHA containing VCO 100 μL (clear), C = MHA containing ampicillin after inoculation with S. aureus (no bacterial growth), D = MHA after inoculation with S. aureus (bacterial growth), E-G = MHA containing VCO 50 μL, 100 μL and 150 μL after inoculation with S. aureus (bacterial bacterial growth), H = MHA containing VCO 200 μL after inoculation with S. aureus (less bacterial growth), I = MHA containing VCO 400 μL after inoculation with S. aureus (no bacterial growth).
Fig. 2Morphology of Staphylococcus aureus after treatment with 250 μL VCO (equal to 0.1275% LA) (a), compare to control of Staphylococcus aureus without treatment (b), examinated with Scanning electron Microscopy (SEM) 15000 x magnification. Yellow arrows indicate holes in the bacterial wall.
The phagocytic activities of mice peritoneal macrophage cells against S. aureus after treatment with VCO.
| Concentration VCO (μL) (1 μL equal to 0.00051% LA) | Number of phagocyted |
|---|---|
| 0 | 23.1 ± 7.52b |
| 50 | 24.7 ± 14.14ab |
| 100 | 26.1 ± 12.94ab |
| 150 | 42.7 ± 18.31ab |
| 200 | 49.1 ± 32.29a |
| 250 | 19.4 ± 16.19b |
Note: Different notations indicate significant differences at the level of 5% (p < 0.05).